Skip to main content

Research Repository

Advanced Search

All Outputs (5)

Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia (2024)
Journal Article
Molica, S., Allsup, D., & Giannarelli, D. (online). Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia. American Journal of Hematology, https://doi.org/10.1002/ajh.27437

The emergence of Bruton's tyrosine kinase (BTK) inhibitors marked a significant advancement in chronic lymphocytic leukemia (CLL) management, especially for high-risk patients. 1 Ibrutinib, the pioneering BTK inhibitor, has undergone extensive study.... Read More about Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia.

Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia—a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial (2024)
Journal Article
Flett, L., Abdelatif, R., Akhtar Baz, S., Brady, S., Corbacho, B., Common, K., Cowling, A., Fairhurst, C., Fitzmaurice, E., Gandhi, S., Hilton, A., Hope, W., Howard, A., Laycock, J., Lillie, P., Mitchell, G., Parker, A., Peel, M., Sheard, L., Sneddon, J., …Barlow, G. (2024). Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia—a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial. Trials, 25(1), Article 427. https://doi.org/10.1186/s13063-024-08272-w

BACKGROUND: Acute leukaemias (AL) are life-threatening blood cancers that can be potentially cured with treatment involving myelosuppressive, multiagent, intensive chemotherapy (IC). However, such treatment is associated with a risk of serious infect... Read More about Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia—a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial.

Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population (2024)
Journal Article
Molica, S., Shanafelt, T. D., Allsup, D., & Giannarelli, D. (2024). Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population. Cancers, 16(6), Article 1085. https://doi.org/10.3390/cancers16061085

To assess the impact of first-line treatment with targeted agents (TAs) or fludarabine, cyclophosphamide, and rituximab (FCR)-based chemo-immunotherapy (CIT) on overall survival (OS) compared to age- and sex-matched individuals in the general populat... Read More about Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population.